application's abstract): The AIDS Clinical Trials Unit (ACTU) at the University of Southern California (USC) was one of the original ACTG units funded in 1986. Since its inception, the USC ACTU has accrued a substantial number of women and patients from ethnic minorities. As an example, in 1998, 19 percent of study patients were women and 81 percent were minorities (61 percent Hispanic, 15 percent non-Hispanic blacks, 4 percent Asian, 1 percent American Indian). Research in the area of opportunistic infections (OIs) has been active. During the first two funding cycles, this Unit led the ACTG in the design and execution of studies for the treatment and prevention of OIs. Moreover, accrual for OI studies at USC represented 38 percent of the total ACTG group effort for OI studies. During these same years, the USC Unit also was active in studies of therapies for HA infection. With the decreasing prevalence of OIs, the USC Unit recently has focused efforts to studies of HIV infection, metabolic and neurologic complications, immune reconstitution, and issues relating to women with HIV. In the last funding period, investigators from USC have held AACTG positions (committee and protocol chairs) and have provided leadership to develop studies to investigate the metabolic dysregulation syndromes (abdominal obesity, insulin resistance, lipid dysregulation, and lipodystrophy) that occur in many patients treated with HAART. These abnormalities can predict that patients with HIV will experience excess morbidity and mortality from cardiovascular complications resulting from accelerated atherogenesis and may be serious complications for persons with HIV. It is proposed that investigators from this Unit will provide leadership in developing the scientific agenda of the ACTG that involves emerging problems during the next funding cycle. The Unit at USC also has had a record of patient retention and data management (endpoint determinations, source documentation, and queries) with consistent monthly scores of 100 points for more than 2 years. Finally, USC continues to accrue subjects (in the range of 100 per year) to primary studies. Thus, the applicants propose that USC has the infrastructure to conduct studies that cover many scientific aims and objectives outlined in the Group Application, to provide scientific leadership in a number of important areas, to assure that quality data is transmitted in a timely manner, and thereby to serve as an integral component of the HIV treatment group.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project--Cooperative Agreements (U01)
Project #
3U01AI027673-18S2
Application #
7150430
Study Section
Special Emphasis Panel (ZAI1)
Program Officer
Germuga, Donna E
Project Start
1992-03-01
Project End
2006-12-31
Budget Start
2006-01-01
Budget End
2006-12-31
Support Year
18
Fiscal Year
2006
Total Cost
$1,493,171
Indirect Cost
Name
University of Southern California
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
072933393
City
Los Angeles
State
CA
Country
United States
Zip Code
90089
Sattler, Fred R; Chelliah, Daniel; Wu, Xingye et al. (2018) Biomarkers Associated with Death After Initiating Treatment for Tuberculosis and HIV in Patients with Very Low CD4 Cells. Pathog Immun 3:46-62
Hulgan, Todd; Stein, James H; Cotter, Bruno R et al. (2013) Mitochondrial DNA variation and changes in adiponectin and endothelial function in HIV-infected adults after antiretroviral therapy initiation. AIDS Res Hum Retroviruses 29:1293-9
Wohl, David A; Kendall, Michelle A; Feinberg, Judith et al. (2013) The clinical impact of continuing to prescribe antiretroviral therapy in patients with advanced AIDS who manifest no virologic or immunologic benefit. PLoS One 8:e78676
Bronke, Corine; Almeida, Coral-Ann M; McKinnon, Elizabeth et al. (2013) HIV escape mutations occur preferentially at HLA-binding sites of CD8 T-cell epitopes. AIDS 27:899-905
Huang, Jeannie S; Hughes, Michael D; Riddler, Sharon A et al. (2013) Bone mineral density effects of randomized regimen and nucleoside reverse transcriptase inhibitor selection from ACTG A5142. HIV Clin Trials 14:224-34
Carlson, Jonathan M; Brumme, Chanson J; Martin, Eric et al. (2012) Correlates of protective cellular immunity revealed by analysis of population-level immune escape pathways in HIV-1. J Virol 86:13202-16
Kang, M; Cu-Uvin, S (2012) Association of HIV viral load and CD4 cell count with human papillomavirus detection and clearance in HIV-infected women initiating highly active antiretroviral therapy. HIV Med 13:372-8
Haubrich, Richard H; Riddler, Sharon A; Ribaudo, Heather et al. (2011) Initial viral decay to assess the relative antiretroviral potency of protease inhibitor-sparing, nonnucleoside reverse transcriptase inhibitor-sparing, and nucleoside reverse transcriptase inhibitor-sparing regimens for first-line therapy of HIV infection AIDS 25:2269-78
Hulgan, Todd; Haubrich, Richard; Riddler, Sharon A et al. (2011) European mitochondrial DNA haplogroups and metabolic changes during antiretroviral therapy in AIDS Clinical Trials Group Study A5142. AIDS 25:37-47
Almeida, Coral-Ann M; Bronke, Corine; Roberts, Steven G et al. (2011) Translation of HLA-HIV associations to the cellular level: HIV adapts to inflate CD8 T cell responses against Nef and HLA-adapted variant epitopes. J Immunol 187:2502-13

Showing the most recent 10 out of 55 publications